Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349703 | 0.93 | HCAR2 (0.61) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349702 | 0.90 | HCAR2 (0.66) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL6781577 | 0.85 | KMT2A (0.58) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349698 | 0.79 | HCAR2 (0.60) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349694 | 0.78 | HCAR2 (0.93) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349695 | 0.77 | HCAR2 (1.00) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349718 | 0.77 | KDM4E (0.51) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL14349712 | 0.77 | KMT2A (0.60) | HCAR2KMT2AMEN1CASP3SENP8 | |
| SCHEMBL13070018 | 0.77 | HDAC1 (0.76) | HDAC1HDAC8 | |
| SCHEMBL14349745 | 0.76 | HCAR2 (0.73) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | HCAR2 20/4885KMT2A 4056/4885MEN1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.